There was no excess of stillbirths, low birthweight or congenital malformations, and no cancers have occurred in the 49 offspring after treatment. There was a significant excess of twins, compared with national expectations, in offspring of female patients (RR=8.52, P=0.025). Aggregation of series from the literature also showed an excess of twins. Chromosomes from cultures of peripheral lymphocytes from 45 children born to 25 patients (11 men and 14 women) after treatment were examined for numerical abnormalities and for structural abnormalities at the 550 or greater band level of resolution. All were normal except in one child with Down's syndrome (47, XY,+21), for whom we found the origin of the trisomy was from the parent without Hodgkin's disease. The chromosome constitution was also abnormal in one miscarriage (69, XXY; originating from the parent without Hodgkin's disease) and one termination (45, X; for which the parental origin could not be determined) after treatment. The study adds to previous questionnaire data and for the first time provides data also from chromosome analysis, that offspring of patients treated in adulthood for Hodgkin's disease are not at greatly raised risk of genotoxic or other adverse outcomes as a consequence of their parent's treatment. The numbers of offspring assessed in the literature remains small, however, and surveillance of larger numbers of subjects is needed to enable reliable treatment-specific analyses.
Radiotherapy and alkylating chemotherapy are known to cause cancer, but whether they can also cause germ cell mutations and hence affect subsequent generations, is uncertain (Draper, 1989) . The offspring of patients with cancer treated by radiotherapy and chemotherapy are important to study in this context since their exposures are large and well-documented. Their risks are also of clinical importance, for counselling of young cancer patients whose fertility is often retained after treatment, and who are uncertain whether to have children. Published studies of the offspring of cancer survivors mainly concern childhood cancer survivors (Mulvihill et al., 1987b; Li et al., 1987; Hawkins, 1991; Green et al., 1991) , many of whom were not treated with potentially mutagenic therapy and whose treatment was many years before conception. Studies of offspring of adult cancer patients have been relatively small, totalling a few hundred children born after treatment. In one study of childhood cancer survivors, chromosomes were examined in 24 offspring (Li et al., 1979) , but no such examinations appear to have been published for offspring of adult cancer patients.
Materials and methods
We studied children of patients treated for Hodgkin's disease at Mount Vernon Hospital, near London, which has been a member of the British National Lymphoma Investigation (BNLI) since 1970. To focus on patients who had an appreciable possibility of having children after treatment, we extracted from the BNLI files, data on all patients with Hodgkin's disease first attending Mount Vernon Hospital during 1970-1991, who had survived to age 18 years and were aged under 40 years (females) or 45 years (males) at incidence of the tumour. The BNLI files and the case-notes of the patients were searched for records of children. Also, we mailed a questionnaire to the patients, and a reminder if necessary, asking about fertility, pregnancies and their outcomes, and the health of the children. When any children conceived after treatment were identified, we requested an interview with the patient, unless psychological problems or illness made this inappropriate. At interview we asked about obstetric history and abnormalities in the children, and whether the patient would agree to blood samples being taken from their children for cytogenetic examination. Counselling was given on the reason for the cytogenetic tests and the consequences of the potential findings, and the patients were told that they could be informed of the results, or not, as they wished. Arrangements were made for specialist genetic counselling, if needed. For patients who agreed, blood samples were taken from all children, whether born before or after treatment. Cultures of peripheral lymphocytes were examined after semi-synchronisation with fluorodeoxyuridine (Webber and Carson, 1983) to detect numerical or structural chromosome abnormality at the 550 or greater band level of resolution. Four G-banded cells were analysed and a total of 10 cells counted in each case. The examination was conducted blind as to whether the child had been born before or after treatment, and the type of treatment. If an abnormality was found, samples were requested from both parents to determine whether the abnormality was a de-novo mutant, and if so, the parental origin of the abnormality, by following the segregation of PCR probes that defined appropriate polymorphisms (Sherman et al., 1994) .
To analyse how birth characteristics of the offspring of the Hodgkin's disease patients compared with the birth characteristics of children in the general population, we calculated relative risks for the Hodgkin's disease offspring (Breslow and Day, 1987), using as the comparison national births data for as many years as available (see Table II ) of the period when the Hodgkin's patients' offspring had been born. Trends in percentages were analysed by the method of Cuzick (1985) ; exact confidence intervals for percentages were based on the binomial distribution.
Results
A total of 340 patients with Hodgkin's disease incident at the study ages and who had survived to at least age 18 years, were treated at Mount Vernon Hospital during 1970-1991. All but 15 (4%) were aged 15 years or more at incidence of the disease, and most [202 (59%)] were male. We examined BNLI records for all of the patients, and case-notes of all patients except ten (seven men, three women) whose case notes could not be traced, and 53 whose notes were not examined because they had died, and either it was known that they had been too ill to conceive or deliver, or it was known by the consultant treating them that they had not in fact had children. At the time of the study 71 of the patients had died, and 27 others were not mailed because no current address could be traced (15), emigration (2), the patient declined to take part during preliminary interviews (3), psychiatric illness (2), or at the consultant's request (5). Questionnaires were sent to the remaining 242 patients (100 women, 142 men), and after reminders replies were received from 143 (59%; similar rates in men and women).
From the case-notes plus questionnaires we found 18 men and 26 women who had had any children born after first treatment for Hodgkin's disease. There were no women for whom children reported in the questionnaire were not already known from the case-notes, except that one patient was among the three women whose notes could not be located. There were six men, however, for whom children were first ascertained from the questionnaire. Eight of the patients with children born after treatment had also had children before treatment; 36 had not. None had conceived children during treatment. The age range at treatment of the men with children conceived after treatment was 10-35 years and for the corresponding women was 14 to 31 years. of Hodgkin's disease was unrelated to the proportion who bore children, but in men the proportion fathering children was lower for those with higher stage disease (P trend < 0.05). In women, the proportion conceiving was greatest for those treated before age 25 (P trend=0.01); in men it was greatest for those treated in their 20s. These results were similar, although less stable based on smaller numbers, when we included patients childless after treatment only if in response to the questionnaire they stated that this was because of infertility due to the disease or its treatment, rather than, for instance, because they did not want children, or their partner was infertile.
We were able to interview 11 of the 18 men and 16 of the 26 women known to have conceived any children after treatment and in all but one instance we gained agreement to take blood specimens from their children. The reasons for non-interview of the remainder were in five that multiple mailings produced no response; for five we did not request interview because the patient was ill or undergoing divorce; two patients declined to be interviewed; two agreed but interview proved impractical; one could not be traced; and two men replied to the questionnaire over a year late, when data collection for the study was completed. For nine of these patients a postal questionnaire had been completed; these questionnaires reported no congenital malformations or cancers in the offspring.
The 27 patients had a total of six liveborn children (three male, three female) before first treatment and 49 liveborn children (24 male, 25 female) after that date. Sixteen of the children were conceived after chemotherapy to the parent, 25 after radiotherapy and eight after combined modality therapy. None of these children were the product of sperm stored before treatment of a male patient, except possibly in (1979, 1987) , Green and Hall (1988) Mongolian blue spot, and a minor birthmark, in children of female patients). 'Macroglossia with a hearing problem' was reported in a child born before treatment to a female patient. Although formal 'expected' rates cannot be calculated precisely, because of differences in methods of data collection, definitions and completeness between our data and malformation registers., the rates of malformation in our patients do not appear to be above those in registry data (Knox and Lancashire, 1991) . No cancers had occurred in the children, among whom at the time of interview 24 were aged 0-4 years, 19 aged 5-9 years and six older than 9 years.
We obtained blood samples from 45 children (one male and one female conceived before treatment; 21 males and 22 females conceived after treatment) of 25 patients. These included four children to men and ten to women after treatment with chemotherapy, 11 to men and ten to women after treatment with radiotherapy (mantle or localised upper body radiotherapy), and seven to men and one to a woman after treatment with combined modalities (in five instances involving radiotherapy directly to the gonads, in the other three involving mantle radiotherapy). All of the samples were normal 46,XY or 46,XX except one child born after treatment who had Down's syndrome, with the chromosome constitution 47,XY,+21. For one further patient we were informed that an intrauterine death had occurred after treatment and the fetus had triploidy. Histopathology indicated a partial hydatidiform mole and we were able to determine the chromosome constitution as 69,XXY. Another patient had a termination of a pregnancy occurring after treatment, for which fetal blood examination showed a 45,X karyotype. The parents of the Down's syndrome patient and the triploid and Turner's fetuses all had normal chromosomes. For the first two of these abnormalities, molecular genetic analyses of DNA showed that the origin of the abnormality was from the patient who had not had Hodgkin's disease; in the third instance (45,X), DNA to determine parental origin could not be extracted from the pathological material available. (Horning et al., 1981) .
Since radiotherapy and several cytotoxic drugs used for cancer chemotherapy are known to be highly mutagenic, it seems reasonable that they might cause germ cell mutations in man (Draper, 1989) . In laboratory animals, radiation and various chemicals applied before mating to males or females have been shown to produce cancers and congenital malformations in the offspring (Nomura, 1982 (Nomura, , 1988 Trasler et al., 1985) . No cancers or apparent excess of congenital malformations occurred in the offspring in our study. Although we cannot be sure whether malformations or cancers occurred in the offspring of subjects who were not interviewed, we know of none, and they did not occur in the nine uninterviewed patients with children after treatment who returned the postal questionnaire. Previous studies overall also do not suggest raised risk of abnormal pregnancy outcomes or childhood cancer from preconceptional exposure to cancer radiotherapy or chemotherapy (Table III) , but based on modest numbers, and with power, especially for childhood cancers (Draper, 1989) , not great. There is also no consistent evidence of transgenerational carcinogenesis in other groups exposed to potential mutagens (Draper, 1989; Yoshimoto et al., 1990; Doll et al., 1994) , and no excess of congenital malformations (Rucknagel, 1981) , but neither our data nor the literature (Table HI) genetic effect is occurring, especially sincexamination of parental chromosomes can determine the parental origin of an abnormality. We found no chromosome abnormalities attributable to the treated parent However, chromosome analysis will not detect subtle changes to the DNA, including conventional mutations. In the general population almost 1% of individuals have a chromosome abnormality when similar levels of banding are used (Jacobs et al., 1992) . Our findings enable us to rule out at the 95% level of confidence that more than 8% of offspring in the study group overall would have had abnormalities, and larger percentages for subgroups of the data. About half of the patients had received chemotherapy and had therefore had a large mutagenic dose to the gonads. The other half had radiotherapy alone, to the upper body, so that their gonadal dose will have been far lower, from scattered radiation. Larger studies with chromosome data would be desirable.
In conclusion, our results and the literature so far are reassuring with respect to pregnancies conceived after chemotherapy and radiotherapy, although the numbers studied are not large enough to exclude quite substantial and important risks or to give satisfactory analyses for specific chemotherapeutic regimens. Further 
